Pharma Mar, S.A. – LSE:0RC6.L
Pharma Mar, S.A. stock price today
Pharma Mar, S.A. key metrics
Market Cap | 16.34B |
Enterprise value | 1.40B |
P/E | 2264.54 |
EV/Sales | 8.39 |
EV/EBITDA | 965.30 |
Price/Sales | 8.37 |
Price/Book | 7.73 |
PEG ratio | 78.59 |
EPS | 0.10 |
Revenue | 162.14M |
EBITDA | -267K |
Income | 2.02M |
Revenue Q/Q | 11.73% |
Revenue Y/Y | -8.46% |
Profit margin | 0.37% |
Oper. margin | -2.83% |
Gross margin | 94.42% |
EBIT margin | -2.83% |
EBITDA margin | -0.16% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePharma Mar, S.A. stock price history
Pharma Mar, S.A. stock forecast
Pharma Mar, S.A. financial statements
| Jun 2023 | 46.21M | 5.02M | 10.87% |
|---|---|---|---|
| Sep 2023 | 37.45M | 1.52M | 4.06% |
| Dec 2023 | 40.51M | -6.81M | -16.83% |
| Mar 2024 | 37.96M | 2.3M | 6.06% |
Paying a dividend greater than earnings.
| Payout ratio | 1836.01% |
|---|
| 2019 | |
|---|---|
| 2020 | 0.68% |
| 2021 | 1.06% |
| 2022 | 1.01% |
| 2023 | 1.55% |
| Jun 2023 | 358690000 | 148.38M | 41.37% |
|---|---|---|---|
| Sep 2023 | 349412000 | 143.21M | 40.99% |
| Dec 2023 | 341223000 | 147.78M | 43.31% |
| Mar 2024 | 333898000 | 141.22M | 42.3% |
| Jun 2023 | -11.44M | -20.34M | -12.16M |
|---|---|---|---|
| Sep 2023 | -6.98M | 6.17M | -6.42M |
| Dec 2023 | -2.68M | 1.66M | -6.31M |
| Mar 2024 | 9.30M | -26.98M | -6.72M |
Pharma Mar, S.A. alternative data
| Aug 2023 | 515 |
|---|---|
| Sep 2023 | 515 |
| Oct 2023 | 515 |
| Nov 2023 | 515 |
| Dec 2023 | 515 |
| Jan 2024 | 515 |
| Feb 2024 | 515 |
| Mar 2024 | 509 |
| Apr 2024 | 509 |
| May 2024 | 509 |
| Jun 2024 | 509 |
| Jul 2024 | 509 |
Pharma Mar, S.A. other data
-
What's the price of Pharma Mar, S.A. stock today?
One share of Pharma Mar, S.A. stock can currently be purchased for approximately $73.87.
-
When is Pharma Mar, S.A.'s next earnings date?
Unfortunately, Pharma Mar, S.A.'s (0RC6.L) next earnings date is currently unknown.
-
Does Pharma Mar, S.A. pay dividends?
Yes, Pharma Mar, S.A. pays dividends and its trailing 12-month yield is 0.81% with 1836% payout ratio.It means that the company is paying a dividend greater than earnings. The last Pharma Mar, S.A. stock dividend of undefined was paid on 31 Aug 2025.
-
How much money does Pharma Mar, S.A. make?
Pharma Mar, S.A. has a market capitalization of 16.34B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 19.45% to 158.15M US dollars.
-
What is Pharma Mar, S.A.'s stock symbol?
Pharma Mar, S.A. is traded on the LSE under the ticker symbol "0RC6.L".
-
What is Pharma Mar, S.A.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Pharma Mar, S.A.?
Shares of Pharma Mar, S.A. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Pharma Mar, S.A. have?
As Jul 2024, Pharma Mar, S.A. employs 509 workers.
-
When Pharma Mar, S.A. went public?
Pharma Mar, S.A. is publicly traded company for more then 9 years since IPO on 5 Nov 2015.
-
What is Pharma Mar, S.A.'s official website?
The official website for Pharma Mar, S.A. is pharmamar.com.
-
How can i contact Pharma Mar, S.A.?
Pharma Mar, S.A. can be reached via phone at +34 918 46 60 00.
Pharma Mar, S.A. company profile:
Pharma Mar, S.A.
pharmamar.comLSE
509
Biotechnology
Healthcare
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
Madrid, 28770
:
:
:
